Axitinib axes assortment of advanced tumours

Axitinib has promising anti-tumour efficacy in the treatment of advanced solid tumours, according to the results of several studies presented at the 14^th Annual European Cancer Conference (ECCO 14) [Barcelona, Spain; September 2007]. More specifically, axitinib was shown to elicit a substantial response in patients with renal cancer refractory to sorafenib, as well as in patients with advanced thyroid cancer. Furthermore, axitinib demonstrated promising efficacy in pancreatic cancer, and as part of a first-line treatment regimen in metastatic breast cancer.